Chennai: Drug major Sun Pharmaceutical Industries Ltd on Monday announced the launch of ready-to-administer cancer drug Gemcitabine InfuSMART in Europe. In a statement, the company said InfuSMART is a technology in which oncology/cancer products were developed in a ready-to-administer bag. "Until now, compounding of oncology products was done at compounding centres or compounded in hospi.. Read More
Sun Pharmaceutical Industries Ltd posted a net profit of Rs. 17136.90 million for the quarter ended March 31, 2016 where as the same was at Rs. 8892.40 - See more at: http://ways2capital-equitytips.blogspot.in/2016/05/sun-pharma-q4-net-profit-at-rs1713690-mn.html#sthash.V5x4pKck.dpuf
Sun Pharmaceutical Industries Ltd announced that one of its subsidiaries has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic version of Gleevec , Imatinib Mesylate tablets 100mg and 400mg Imatinib Mesylate tablets,
Sun Pharma gains after USFDA approval:Sun Pharmaceutical Industries advanced almost a percent to Rs 841.75 on BSE after the company said it received US drug regulator's approval for abbreviated new drug application for generic version of Glumetza tablets.The company will announce Q1 results on 12 August 2016.
Here’s a round-up of the stories thus far: Reuters: FDA bans imports from Sun Pharma plant in India crackdown The U.S. Food and Drug Administration (FDA) has banned imports from Indian generic drugmaker Sun Pharmaceutical Industries Ltd’s plant at Karkhadi in the western state of Gujarat, in the latest quality blow for India’s drug sector. …
Shares of Sun Pharmaceutical Industries Ltd are currently trading 1.50% higher at Rs. 770.35 on BSE after it was reported by a financial daily that the company will raise Rs. 1,000 crore from the domestic bond market via its arm Sun Laboratories.